Precision-oncology therapeutics
| Filer | 13FScore | This quarter | Shares | Value | % of their book |
|---|---|---|---|---|---|
| Stanley Druckenmiller / Duquesne | 91 | New buy | 221,112 | $7,080 | 0.2% |
| Steve Cohen / Point72 | 75 | Added +6% | 790,494 | $25,311,618 | 0.0% |
| Filed | Form | Activist | % of class | Conviction | |
|---|---|---|---|---|---|
| 2026-03-31 | SCHEDULE 13D/A | Fairmount Funds Management LLC | 8.6% | High | filing |
| 2026-01-22 | SCHEDULE 13D/A | Fairmount Funds Management LLC | 9.9% | High | filing |
Every tracked holder of this name, sorted new → added → flat → trimmed. Shares = reported 13F share count; Value as reported (a few managers file values in $thousands). Generated 2026-11-17.